Matt [on for Salveen Richter]

Managing Director and Lead Analyst for the U.S. Biotechnology sector at Goldman Sachs

Salveen Richter is a Managing Director and Lead Analyst for the U.S. Biotechnology sector at Goldman Sachs, focusing on cutting-edge developments in gene editing and biopharmaceuticals. She actively covers a broad range of publicly traded biotech companies including Sarepta Therapeutics, Moderna, and Intellia Therapeutics, earning recognition for a strong track record with a TipRanks success rate of 40% and an average return per rating of 8.1%, with standout calls such as a +569% return on Intellia Therapeutics. Salveen began her career after earning a bachelor's degree from Johns Hopkins University, and has held progressively senior roles in equity research before joining Goldman Sachs, where she is frequently featured in leading financial media. She is known for her in-depth industry expertise and is registered with FINRA, holding relevant securities licenses required for her senior research analyst position.